Executive Summary
Eight products researched across regulatory and insurance coverage domains. Exact Sciences' portfolio spans colorectal cancer screening, multi-cancer detection, precision oncology, and hereditary cancer testing. Coverage varies dramatically based on FDA status and clinical evidence maturity.
Key Findings: FDA-approved products (Cologuard, Cologuard Plus) enjoy universal Medicare and private insurance coverage with zero patient cost-sharing for eligible screening. Established LDTs (Oncotype DX, OncoExTra, Riskguard, Oncodetect) have secured Medicare coverage through NCDs and LCDs, with broad private payer acceptance. Newly launched LDTs face coverage barriers: Cancerguard, despite September 2025 launch, remains uncovered by Medicare and most private insurers as an investigational multi-cancer screening test.
Comprehensive Product Coverage Table
| Product | FDA Status | Launch Date | Medicare Coverage | Medi-Cal Coverage | Private Insurance |
|---|---|---|---|---|---|
| Cologuard | FDA PMA (P130017) - Aug 2014 | 2014 | YES NCD 210.3, CPT 81528, $509 | YES $0 cost sharing | Broadly covered 96%+ patients $0 OOP |
| Cologuard Plus | FDA PMA (P230043) - Oct 2024 | March 2025 | YES CPT 0464U, $592 | YES California in-network | MA transitioning |
| Cancerguard | LDT - NOT FDA approved | Sept 2025 | NO investigational | NO not covered | NO investigational |
| Oncodetect | LDT - NOT FDA approved | April 2025 | YES MolDX LCDs (July 2025) | Likely YES follows Medicare | major insurers |
| Oncotype DX | LDT - NOT FDA approved | 2004 | YES Multiple LCDs, CPT 81519, $3,416 | YES available to Medicaid | Broadly covered all major insurers |
| OncoExTra | LDT - NOT FDA approved | Feb 2023 | YES NCD 90.2, NGS codes | Available follows Medicare | Broadly covered 150M+ lives, 98% $0 OOP |
| Riskguard | LDT - NOT FDA approved | March 2024 | YES NCD 90.2/LCD L38972 | YES TAR may be required | Covered UHC, Anthem, Cigna, Humana |
| Oncotype DX DCIS | LDT - NOT FDA approved | Dec 2011 | YES Part of Oncotype suite, ~$3,400 | YES Available to Medicaid | Broadly covered Major insurers, 86-91% pay $0 |
| Oncotype DX Colon | LDT - NOT FDA approved | Jan 2010 | YES PLA 81525, ~$3,400 | YES Part of Oncotype coverage | Broadly covered All major insurers |
| PreventionGenetics Portfolio | LDT - NOT FDA approved | Acquired Dec 2021 | YES Varies by test, $0 when criteria met | Available Varies by state, TAR required | Widely covered Varies by test and insurer |
Detailed Product Analysis
1. COLOGUARD FDA Approved
Original Colorectal Cancer Screening
Regulatory Status
- FDA Classification: PMA Approval (Class III Medical Device)
- PMA Number: P130017, approved August 11, 2014
- Clinical Trial: DeeP-C study (NCT01260168) with 10,000 patients
- NOT an LDT: This is a fully FDA-approved device
- 2019 Update: FDA expanded age indication to 45+ (previously 50+)
Medicare Coverage ✅ COVERED
- NCD: 210.3 - Colorectal Cancer Screening Tests
- CPT Code: 81528
- Reimbursement: $492.72 (Medicare Fee-For-Service)
- Age: 45-85 years old
- Frequency: Once every 3 years
- Cost Sharing: $0 copayment, $0 coinsurance, $0 deductible
- Eligibility: Average-risk, asymptomatic patients only
Medi-Cal Coverage ✅ COVERED
- California law (effective Jan 2022) requires coverage of USPSTF Grade A colorectal screening
- CPT 81528 covered with same criteria as Medicare
- AB 342 (2021): Eliminates cost sharing for entire CRC screening process
- Prior Authorization: Generally not required for eligible patients
Private Insurance Coverage ✅ BROADLY COVERED
- ACA Mandate: Required coverage as USPSTF Grade A preventive service
- 96%+ of patients have $0 out-of-pocket cost
- In-Network: UnitedHealthcare (July 2017), Anthem (2016), Aetna (April 2015), Cigna, BCBS affiliates
- Coverage Criteria: Ages 45+, average risk, once every 3 years
2. COLOGUARD PLUS FDA Approved
Next-Generation CRC Screening
Regulatory Status
- FDA Classification: PMA Approval (Class III Medical Device)
- PMA Number: P230043, approved October 3, 2024
- Clinical Trial: BLUE-C study (NCT04144738) with 20,000+ patients
- NOT an LDT: This is a fully FDA-approved device
- Performance Improvements: 95% cancer sensitivity (vs. 92% original), 43% advanced adenoma sensitivity, reduces false positives by ~40%
Medicare Coverage ✅ COVERED
- NCD: 210.3 (updated Oct 3, 2024 for Cologuard Plus)
- CPT Code: 0464U (proprietary code)
- Reimbursement: $592.00 (approximately 20% increase over original)
- Same eligibility: Ages 45-85, average risk, every 3 years
- Available since: March 2025
Private Insurance Coverage
- Medicare Advantage: Transitioning (Humana announced in-network Aug 2025 for 5.8M members)
- Commercial Payers: Slower rollout; 35-40% of Cologuard volumes expected to transition in 2025
- Reimbursement Timeline: Full commercial parity expected by 2026 (18-24 months post-launch)
- Q2 2025 Performance: Record 200,000+ provider orders
3. CANCERGUARD LDT
Multi-Cancer Early Detection Test
Regulatory Status
- FDA Status: NOT FDA-approved or cleared
- Classification: Laboratory Developed Test (LDT)
- Launch Date: September 10, 2025
- Test Type: Blood-based multi-cancer early detection (MCED) analyzing circulating tumor DNA and tumor-associated proteins
- Indication: Adults ages 50-84, screens for 50+ cancer types (excludes breast/prostate)
- FDA Oversight: Falcon registry study under FDA-reviewed IDE (25,000 participants)
Medicare Coverage ❌ NOT COVERED
- Status: No Medicare coverage as of October 2025
- Reason: Not FDA-approved; MCED tests considered investigational/experimental
- No NCD or LCD exists
- Legislative Effort: H.R. 842/S. 339 (Nancy Gardner Sewell Medicare MCED Screening Coverage Act) introduced January 2025
- Out-of-Pocket Price: $689
Medi-Cal Coverage ❌ NOT COVERED
- No specific Medi-Cal policy for MCED tests
- Investigational tests without FDA approval unlikely to be covered
- Medi-Cal typically covers FDA-approved cancer screening only
Private Insurance Coverage ❌ NOT COVERED BY MOST PLANS
- Industry Consensus: MCED tests are "investigational" without sufficient clinical utility evidence
- Blue Cross Blue Shield: Explicit non-coverage policy (Medical Policy #124) - MCED testing is "INVESTIGATIONAL" and "not a covered service"
- Other Major Insurers: No coverage policies for UnitedHealthcare, Anthem, Aetna, Cigna
- Patient Responsibility: $689 out-of-pocket
4. ONCODETECT LDT
Molecular Residual Disease Test
Regulatory Status
- FDA Status: NOT FDA-approved or cleared
- Classification: Laboratory Developed Test (LDT)
- Launch Date: April 2025
- Test Type: Tumor-informed ctDNA assay for minimal/molecular residual disease (MRD) detection
- Variants Tracked: Up to 200 patient-specific tumor variants (personalized panel created via whole exome sequencing, not a fixed gene set)
- Detection Sensitivity: Identifies 1 ctDNA molecule in 20,000 cfDNA molecules (15 parts per million limit of detection)
- Indication: Post-surgical monitoring for colorectal cancer recurrence
Medicare Coverage ✅ COVERED (CRC Only)
- MolDX Coverage: July 2025 (just 2.5 months after launch)
- Technical Assessments: Multiple MolDX LCDs for tumor-informed MRD
- Covered Indication: Colorectal cancer only
- Requirements: Personalized assay design, validated tumor tissue
Private Insurance Coverage
- Major insurers covering for colorectal cancer MRD testing
- Follows MolDX coverage determinations
- Pre-authorization may be required
5. ONCOTYPE DX LDT
Genomic Tumor Profiling for Treatment Decisions
Regulatory Status
- FDA Status: NOT FDA-approved or cleared
- Classification: Laboratory Developed Test (LDT)
- Launch Date: 2004
- Indication: Breast, colon, prostate cancer treatment planning
- Clinical Validation: Extensive peer-reviewed evidence over 20+ years
Medicare Coverage ✅ BROADLY COVERED
- Multiple LCDs for different cancer types
- CPT Code: 81519 (breast cancer)
- Reimbursement: $3,416 for breast cancer test
- Covered for: Early-stage breast cancer, colon cancer (Stage II/III), prostate cancer
Private Insurance Coverage ✅ BROADLY COVERED
- All major insurers cover Oncotype DX
- Included in clinical practice guidelines (NCCN, ASCO)
- Generally requires pathology-confirmed diagnosis
6. ONCOEXTRA LDT
Comprehensive Genomic Profiling (CGP) for Advanced Cancer
Regulatory Status
- FDA Status: NOT FDA-approved or cleared
- Classification: Laboratory Developed Test (LDT)
- Launch Date: February 2023
- Test Type: Next-generation sequencing (NGS) panel
- Genes Analyzed: Approximately 20,000 genes and 169 introns (whole exome and whole transcriptome sequencing), tumor mutational burden (TMB), microsatellite instability (MSI)
Medicare Coverage ✅ COVERED
- NCD 90.2: Next Generation Sequencing for recurrent/metastatic/advanced cancers
- MolDX Coverage: Technical assessments approved
- NGS Codes: CPT 81445, 81455, 81479
- Indication: Recurrent, relapsed, refractory, metastatic, or advanced Stage III/IV cancer
Private Insurance Coverage ✅ BROADLY COVERED
- Coverage: 150M+ lives
- 98% of patients have $0 out-of-pocket cost
- In-Network: All major insurers
7. RISKGUARD LDT
Hereditary Cancer Testing
Regulatory Status
- FDA Status: NOT FDA-approved or cleared
- Classification: Laboratory Developed Test (LDT)
- Launch Date: March 2024
- Test Type: Multi-gene hereditary cancer panel
- Genes: 59 genes associated with hereditary cancer syndromes across 11 common cancer types
Medicare Coverage ✅ COVERED (Diagnostic Only)
- NCD 90.2: Diagnostic Testing for beneficiaries with cancer
- LCD L38972: MolDX Germline Genetic Testing for Cancer Susceptibility
- Not covered: Predictive/screening testing for asymptomatic individuals
- Requirements: Personal cancer history, clinical indication, treating physician order
Medi-Cal Coverage ✅ COVERED
- Available to Medicaid enrollees
- Covers Lynch Syndrome testing, HBOC testing, hereditary colon cancer panels
- TAR: Treatment Authorization Request may be required
- Genetic counseling coverage available (HCPCS S0265)
Private Insurance Coverage ✅ COVERED
- In-Network: UnitedHealthcare, Anthem, Cigna, Humana
- Requirements: Personal cancer history OR significant family history
- Pre-test genetic counseling strongly recommended
- Pre-authorization may be required
8. ONCOTYPE DX DCIS LDT
Test Type: 12-gene mRNA expression profiling for ductal carcinoma in situ (DCIS) - non-invasive breast cancer. Helps predict recurrence risk and guide treatment decisions.
Regulatory Status: Laboratory Developed Test (LDT) - CLIA/CAP certified, NOT FDA approved
Launch: December 2011 | Acquired by Exact Sciences in 2019
Medicare Coverage (National)
✓ COVERED
- Status: Covered as part of Oncotype DX suite
- Reimbursement: ~$3,400 (similar to Oncotype DX Breast)
- Patient Cost: $0 for Medicare fee-for-service when criteria met
- Clinical Use: DCIS patients considering breast-conserving surgery
Medicaid Coverage
✓ AVAILABLE
- Available to Medicaid beneficiaries
- Follows similar criteria as Oncotype DX Breast
Private Insurance Coverage
✓ BROADLY COVERED
- Major Insurers: Aetna, Anthem, Cigna, Humana, UnitedHealthcare
- Patient Cost: Most patients pay $0-$100 (86-91% pay $0)
- Coverage Criteria: DCIS diagnosis, ER-positive, considering lumpectomy
Biomarkers: 12-gene mRNA expression panel (7 cancer-related + 5 reference genes including Ki-67, AURKA, BIRC5)
9. ONCOTYPE DX COLON LDT
Test Type: 12-gene recurrence score test for Stage II colon cancer. Predicts recurrence risk and helps determine need for adjuvant chemotherapy.
Regulatory Status: Laboratory Developed Test (LDT) - CLIA/CAP certified, PLA Code 81525
Launch: January 2010 | Acquired by Exact Sciences in 2019
Medicare Coverage (National)
✓ COVERED
- Status: Covered as part of Oncotype DX suite
- Reimbursement: ~$3,400
- Patient Cost: $0 for Medicare fee-for-service when criteria met
- Clinical Use: Stage II colon cancer, post-surgery, considering chemotherapy
Medicaid Coverage
✓ AVAILABLE
- Available to Medicaid beneficiaries
- Part of Oncotype coverage policies
Private Insurance Coverage
✓ BROADLY COVERED
- Major Insurers: All major commercial insurers cover the test
- Patient Cost: Most patients pay $0-$100
- Coverage Criteria: Stage II colon cancer, post-surgical, deciding on adjuvant therapy
Biomarkers: 12-gene mRNA expression (7 cancer-related + 5 reference genes, including stromal and cell cycle genes)
Clinical Evidence: Validated in multiple clinical trials for Stage II colon cancer risk stratification
10. PREVENTIONGENETICS PORTFOLIO LDT
Test Type: Comprehensive genetic testing portfolio with 5,000+ distinct tests covering nearly all clinically relevant genes. Includes hereditary cancer panels, whole exome sequencing (WES), and whole genome sequencing (WGS).
Regulatory Status: Laboratory Developed Tests (LDTs) - CLIA-certified, CAP-accredited laboratory with 25+ PhD geneticists
Acquisition: December 2021 for $190M (Founded 2004) | Had approximately $36M revenue in 2021; current revenue not separately disclosed
Medicare Coverage (National)
✓ COVERED (Varies by Test)
- Status: Coverage varies by specific test type
- Hereditary Cancer Panels: Covered when criteria met (55 genes, 11+ cancer types)
- Patient Cost: $0 when medical necessity criteria met
- Requirements: Personal or family cancer history, genetic counseling recommended
Medicaid Coverage
✓ AVAILABLE (Varies by State)
- Varies by test and state Medicaid program
- TAR (Treatment Authorization Request): May be required
- Hereditary cancer testing: Generally covered with clinical justification
Private Insurance Coverage
✓ WIDELY COVERED (Varies by Test and Insurer)
- Coverage: Varies by specific test and insurance plan
- Patient Cost: $0 when covered; commercial payers widely cover hereditary cancer testing
- Pre-authorization: Often required
- STAT Testing: +25% fee for expedited results (3 weeks standard, 2 weeks STAT)
Pricing Structure
Hereditary Cancer Panels: $540-$590 (55 genes across 11+ cancer types)
PGxome (Whole Exome Sequencing): Standard $990; Rapid $2,290 (14-day expedited turnaround) | Includes CNV analysis, free reflex testing
Standard Tests: $990 or less for most tests
Custom Panels: Variable pricing based on gene count and complexity
Sponsored No-Cost Testing Programs
- Movement Disorders: 938 genes (Mirum Pharmaceuticals sponsored)
- TTR Amyloidosis: AstraZeneca/Ionis sponsored
- Acute Hepatic Porphyria: Alnylam sponsored
- Auditory Neuropathy: Regeneron's Amplify program
Biomarkers: Germline DNA/RNA sequencing - WES (PGxome), WGS (PGnome), custom gene panels available
Laboratory: CLIA-certified, CAP-accredited with 25+ PhD geneticists on staff
Summary: Coverage Patterns and Insights
FDA approval is the critical gateway to universal coverage. Both Cologuard products achieved immediate, comprehensive Medicare and private insurance coverage upon FDA PMA approval, with zero patient cost-sharing for eligible screening. This contrasts sharply with Cancerguard's investigational status and lack of coverage despite high clinical interest.
Established LDTs can achieve broad coverage through evidence accumulation. Oncotype DX (launched 2004) and OncoExTra (launched 2023) secured Medicare NCDs and broad private payer acceptance through clinical validation and demonstrated utility, despite never obtaining FDA approval. The key differentiator is clinical use case: diagnostic and treatment-guiding tests receive coverage more readily than screening tests.
Timing matters for new LDT launches. Oncodetect achieved Medicare coverage just 2.5 months post-launch (April to July 2025) through the MolDX program for colorectal cancer MRD testing. This rapid coverage reflects Medicare's structured pathway for molecular diagnostics with demonstrated clinical validity. Cancerguard, by contrast, faces the challenging MCED coverage landscape where no product has secured Medicare coverage without FDA approval.
Medi-Cal generally mirrors Medicare coverage decisions but with more stringent documentation requirements and potential prior authorization barriers, particularly for high-cost molecular diagnostics. California state law (AB 342) provides strong protection for colorectal cancer screening, ensuring both Cologuard products are covered without cost-sharing.
Private insurers follow evidence hierarchies. ACA mandates drive coverage for USPSTF Grade A/B preventive services (Cologuard benefits directly). For oncology diagnostics, insurers established coverage for Oncotype DX before Medicare did (2005-2008 vs. 2006), demonstrating commercial payer willingness to cover validated precision medicine tests. Major insurers maintain in-network relationships with Exact Sciences, facilitating coverage for appropriate tests with established clinical utility.
The $689 price point for Cancerguard reflects self-pay reality for MCED tests awaiting both regulatory approval and coverage determinations. The Nancy Gardner Sewell Medicare MCED Screening Coverage Act represents industry efforts to create legislative pathways analogous to how mammography and colonoscopy screening gained Medicare coverage, but passage and implementation remain uncertain.